anti-CD40-XTEN

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD40-XTEN
Drug Alias NameCD40 ligand receptor antagonist XTEN (Amunix)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsRejection of organ transplantationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmunix Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmunix Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A